A Phase 2 interventional study of BAY94-8862 and BAY94-8862 in Diabetic Nephropathies, sponsored by Bayer. Completed at 16 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-16.
Sponsored by Bayer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing finerenone in Diabetic Nephropathies — 5 open to participants now, 5 under way, 1 of them phase 3. finerenone · Diabetic Nephropathies.
Among the 10 studies testing finerenone in Diabetic Nephropathies, this one is the 6th largest by enrollment, is one of 2 that started in 2013, is one of 2 in phase 2, and was the 2nd registered.
543 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.
Browse Diabetic Nephropathies studies →5 of the 10 studies testing finerenone in Diabetic Nephropathies are open now, in 3 countries. Recruiting first, the newest first:
Huijie Zhang · Sites in China
Ages 18–70
Washington D.C. Veterans Affairs Medical Center · Sites in United States
Ages 20–90
Chittagong Medical College · Sites in Bangladesh
Ages 18+
Hospital de Messejana Dr. Carlos Alberto Studart Gomes
Ages 18+
College of Physicians and Surgeons Pakistan
Ages 18+
By country, each count listing its studies:
finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 96 is above the median of 78 across 388 interventional studies indexed under Diabetic Nephropathies.
Median enrollment 108 across the 10 interventional studies. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 10 have an industry lead sponsor. The 6 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Bayer has 8 studies filed under Diabetic Nephropathies — fewer than ten, so there is no comparison to draw.
2 of the studies testing finerenone in Diabetic Nephropathies that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07598864Phase 3Chittagong Medical College"Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With Type 2 Diabetes" | 2027-05-01 |
| NCT07155694Washington D.C. Veterans Affairs Medical CenterRole of Finerenone in African American Veterans With Diabetic Kidney Disease | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing finerenone in Diabetic Nephropathies, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will be conducted in Japanese subjects with type 2 diabetes mellitus and the clinical diagnosis of Diabetic Nephropathy( DN) using a multi-center, randomized, adaptive, double-blind, placebo-controlled, parallel-group design.
Primary objective of the study is investigate the change of Urinary Albumin to Creatine Ratio (UACR) after treatment with different oral doses of BAY94-8862 given once daily from baseline to Visit 8 (Day 90)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects with a clinical diagnosis of Diabetic Nephropathy (DN) based on at least 1 of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BAY94-8862
Drug: BAY94-8862
Drug: BAY94-8862
Drug: BAY94-8862
Drug: BAY94-8862
Drug: Placebo
Drug: BAY 94-8862
Drug: BAY 94-8862
1.25 mg BAY94-8862 tablet once daily in the morning
2.5 mg BAY94-8862 tablet once daily in the morning
5 mg BAY94-8862 tablet once daily in the morning
7.5 mg BAY94-8862 tablet once daily in the morning
10 mg BAY94-8862 tablet once daily in the morning
Placebo tablet once daily in the morning
15 mg BAY 94-8862 tablet once daily in the morning
20 mg BAY 94-8862 tablet once daily in the morning
Change of urinary albumin-to creatinine ratio
Time frame: Baseline and 90 days
Change in serum potassium concentration
Time frame: Baseline and 90 days
Ran from Oct 2013 to primary completion in Oct 2014, 11 months.
Of 32 industry-sponsored phase 2 interventional studies under Diabetic Nephropathies, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 11 months is below that.
Counting every sponsor, half of 52 studies reached it within 21 months; a quarter within 13 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Finerenone